Bevacizumab for the treatment of recurrent glioblastoma. - Wikidata - wikimedia - TriplyDB

Bevacizumab for the treatment of recurrent glioblastoma.

Bevacizumab for the treatment of recurrent glioblastoma.

http://www.wikidata.org/entity/Q34982777

about

Recent developments in receptor tyrosine kinases targeted anticancer therapy Dynamic quantitative intravital imaging of glioblastoma progression reveals a lack of correlation between tumor growth and blood vessel density Glioblastoma, hypoxia and autophagy: a survival-prone 'ménage-à-trois'Adaptation to antiangiogenic therapy in neurological tumors Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma.Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma.Glioblastoma multiforme - an overview.Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution.Antiangiogenic therapy for glioma.Glioma revisited: from neurogenesis and cancer stem cells to the epigenetic regulation of the niche Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited.Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.Bevacizumab for glioblastoma: current indications, surgical implications, and future directions Breast cancer brain metastases: new directions in systemic therapy Safety and efficacy of carmustine (BCNU) wafers for metastatic brain tumors.Anti-cancer Therapies in High Grade Gliomas.Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme Pseudoprogression and pseudoresponse in the management of high-grade glioma : optimal decision timing according to the response assessment of the neuro-oncology working group.Anti-angiogenic drug discovery: lessons from the past and thoughts for the future.Bevacizumab for the treatment of glioblastoma.Bevacizumab for glioblastoma-a promising drug or not?Assessment methods for angiogenesis and current approaches for its quantification Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.Newcastle disease virus interaction in targeted therapy against proliferation and invasion pathways of glioblastoma multiforme.Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier.HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies.Investigational new drugs for brain cancer.Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.Temozolomide nanoparticles for targeted glioblastoma therapy.Secreted meningeal chemokines, but not VEGFA, modulate the migratory properties of medulloblastoma cells.Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer.Nanoparticles of carbon allotropes inhibit glioblastoma multiforme angiogenesis in ovo.Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma.The combinational therapy of trastuzumab and cetuximab inhibits tumor growth in a patient-derived tumor xenograft model of gastric cancer.

P2860

Q26751331-139F9F82-E624-4EF0-8228-0FB27F180B98 Q27308856-9593B535-14D4-4E37-BE9A-2239D168BD4E Q28067399-4BEF6698-2BBF-4A32-8583-D98D5ECA866D Q28082908-D966B6E8-8C7D-4453-9CBA-BDB6C50090CB Q30831967-F43B5D3F-8561-4391-A8B8-306321D43D7C Q31131751-06C342B7-C7EE-45AD-B710-BE120358DEC0 Q33625227-8833E898-F907-4676-9A92-73A560D9D9E3 Q33668084-7A71BE0C-694B-41DC-BE79-F9FD4BD39BCC Q34417525-44852477-C486-4AD2-AD51-1D1C337ABE52 Q34589068-C521B775-D941-4C9A-8E99-22DDDD14176E Q34978253-DC597F3F-B759-418B-95DF-FB0F35A545F9 Q36101999-90FD3EB0-A090-4020-B044-95EE30AAC197 Q36225175-9E819D41-729E-4D08-9B75-5FBFC789B89D Q36428702-837C61AE-C99C-425F-95F8-2F78E7F504AF Q36542980-17988210-6BB0-45DD-91D8-D8E51899B394 Q36544122-E782C8CC-8E35-41E1-A3F5-018C0EE93604 Q36785131-36C20F91-85ED-4B67-8885-118FF5C0CB50 Q36822207-9094FCC9-117F-44C1-AB06-9C1AB75B0CF8 Q36822500-12D3967D-72C6-45F7-AEC8-722A6E2BC50F Q36898626-B2DFF999-F393-43B7-A383-E941197A8570 Q37290626-F8F77960-8A71-4168-AAD3-A76926EAE943 Q37372416-6EABE27B-6912-4C2B-8E95-3248909745D1 Q37591724-08CBE0CE-7A29-4A9C-8347-A02093476569 Q38020234-255BACB7-1D9E-41E8-B4F8-CA2A21DD2377 Q38129428-13A2600D-374D-4795-8A22-7527541DC8AD Q38161401-0F87A150-A87B-4217-8E64-3E1C8534B395 Q38225523-1C2B12ED-6A81-4E0C-A3F5-870365F2ADD7 Q38241483-97A39505-5678-4EE0-A1B6-F262ACC860C8 Q38245925-BFC979B8-5495-4809-AC41-BB67B89F50B2 Q38253056-0B493CC5-C312-495F-904A-2234D096C478 Q38351134-B4E90629-52FB-4FF5-8FD1-27B455D66955 Q38825960-76522013-3594-4BB1-B881-E35F2CA61B9C Q38832510-53573C26-0181-4F40-8EBB-4F0D57CE305C Q38897023-1313745A-2FC0-4CFA-B627-A12690642539 Q38902260-9A8675FD-596C-4AA5-A66E-C1AE01D35CF8 Q38984930-682FDD44-6EC9-47DB-86AD-398DD71FBBEB Q38985337-7899C0BE-D398-4BB9-A90A-BBD3A142767C Q39429294-752ADA55-5265-4D87-A55F-1FB2DADC2B52 Q39597202-5445B5CC-A1D8-408A-8A1B-96060128882C Q40539652-A6E4A159-8135-4292-9F0D-6D947E73E6DD

P2860

Bevacizumab for the treatment of recurrent glioblastoma.

http://www.wikidata.org/entity/Q34982777

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Bevacizumab for the treatment of recurrent glioblastoma.

@ast

Bevacizumab for the treatment of recurrent glioblastoma.

@en

Bevacizumab for the treatment of recurrent glioblastoma.

@nl

type

label

Bevacizumab for the treatment of recurrent glioblastoma.

@ast

Bevacizumab for the treatment of recurrent glioblastoma.

@en

Bevacizumab for the treatment of recurrent glioblastoma.

@nl

prefLabel

Bevacizumab for the treatment of recurrent glioblastoma.

@ast

Bevacizumab for the treatment of recurrent glioblastoma.

@en

Bevacizumab for the treatment of recurrent glioblastoma.

@nl

P1433

Q34982777-20670ED6-4447-49D3-A86C-305387D7FC12

P1476

Q34982777-117B177C-D07E-444A-A788-3997A9C8ADAD

P2093

Q34982777-D3C679F3-0197-41FC-A977-1827EC475481

P2860

Q34982777-00D907E9-80E7-4717-A8F0-7748E293904D

Q34982777-01234FCE-2A70-4647-894B-2D63473CC88C

Q34982777-012AE8CF-4097-41AB-BC14-4502013D57A4

Q34982777-02F27437-7788-44DE-A06A-9007F9550DB0

Q34982777-05F2DC99-3936-4B60-BF2A-8BF9D1562984

Q34982777-06C0FC2C-FF32-46B3-856D-CCBBA0A90759

Q34982777-0B92CBFA-343A-4DEA-B9D2-CCE731747A0A

Q34982777-0E0001E2-9427-489E-A4AD-621805322857

Q34982777-1AF698CA-7981-4626-A24B-A9B2B17D2BAC

Q34982777-1E70172F-0BF2-49DF-B773-968677B5ED41

P304

Q34982777-18A968EB-6585-4465-8353-8CCE03C16AA6

P31

Q34982777-85CF6C38-410B-46CE-A804-1CE8BFA544C6

P356

Q34982777-EEAD15FF-1AE3-41FA-AE7B-8F81B20549B0

P407

Q34982777-B3DAFCDA-B2DB-4452-869D-9A1DB0488BD5

P478

Q34982777-DDAA4436-72C5-43F0-8A23-83E24EC76AF1

P577

Q34982777-5D0BE9B0-DD61-429A-AAB3-6C4D56643EE1

P698

Q34982777-6174EC02-E974-4004-9B41-C67C4F779B6B

P921

Q34982777-28EE64FE-FF5F-47D0-939B-B11CC582A7C7

P932

Q34982777-B4326893-DFF6-4BFF-B542-565AD573C872

P356

P1433

Clinical Medicine: Oncology

P1476

Bevacizumab for the treatment of recurrent glioblastoma.

@en

P2093

Marc C Chamberlain

http://www.w3.org/2001/XMLSchema#string

P2860

Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

Tumor angiogenesis: therapeutic implications

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

A perivascular niche for brain tumor stem cells

P304

117-129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4137/CMO.S7232

http://www.w3.org/2001/XMLSchema#string

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21603247

http://www.w3.org/2001/XMLSchema#string

P921

P932

3095028

http://www.w3.org/2001/XMLSchema#string